Cancer Program

Targeted BMI1 inhibition impairs tumor growth lung adenocarcinomas with low CEBPα Expression

August 3, 2016

Researchers at the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS), in collaboration with Harvard Stem Cell Institute (HSCI), have discovered a new way in which the development of lung cancer can be stopped. In a study published in Science Translational Medicine, the researchers found that inhibiting a protein called BMI1 impaired tumour growth in lung cancer.

The study was led by HSCI Principal Faculty member Daniel Tenen, MD, his associate Elena Levantini, PhD, and included first author Dr Kol Jia Yong, a former CSI… Read more about Targeted BMI1 inhibition impairs tumor growth lung adenocarcinomas with low CEBPα Expression

Breaking leukemia's rhythm

April 7, 2016

New study shows that circadian rhythm circuitry is essential for acute myeloid leukemia stem cells but not healthy blood cells, suggesting possible pathways for therapeutics

By Veronica Meade-Kelly, the Broad Institute of MIT and Harvard

According to a… Read more about Breaking leukemia's rhythm

Bone drug kills resistant cancer stem cells by making home unlivable

November 6, 2013

A bone drug already on the market for osteoporosis may kill chronic myelogenous leukemia (CML) stem cells thought to persist in the bone marrow after standard therapy, lowering the likelihood of disease recurrence, according to a new study in mice led by researchers at the Harvard Stem Cell Institute (HSCI), the Harvard Department of Stem Cell and Regenerative Biology, and Massachusetts General Hospital.… Read more about Bone drug kills resistant cancer stem cells by making home unlivable